• Home
  •  / GenMark Diagnostics

GenMark Diagnostics

OverviewSuggest Edit

GenMark Diagnostics is a provider of automated, multiplex molecular diagnostic testing systems. The Company develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.  It offers four Food and Drug Administration -cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. GenMark also offers a Hepatitis C genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only. 

TypePublic
Founded2010
HQCarlsbad, USMap
Websitegenmarkdx.com
Employee Ratings2.6More
Overall CultureC+More
View Jobs (24)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)437(-8%)
Job Openings24
Revenue (FY, 2019)$88 M(+68%)
Share Price (Nov 2020)$13.6
Cybersecurity ratingAMore

Key People/Management at GenMark Diagnostics

Scott Mendel

Scott Mendel

President and Chief Executive Officer
Michael Gleeson

Michael Gleeson

Senior Vice President, Corporate Accounts
Johnny Ek

Johnny Ek

Chief Financial Officer
Michael Harkins

Michael Harkins

Senior Vice President, Sales
Brian Mitchell

Brian Mitchell

Senior Vice President, Operations
Eric Stier

Eric Stier

Senior Vice President, General Counsel and Secretary
Show more

GenMark Diagnostics Office Locations

GenMark Diagnostics has offices in Carlsbad, Albany, Atlanta, Birmingham and in 29 other locations
Carlsbad, US (HQ)
5964 La Place Ct
Albany, US
Albany, NY, USA
Atlanta, US
Atlanta, GA, USA
Birmingham, US
Birmingham, AL, USA
Boston, US
Boston, MA, USA
Bristol, US
Bristol, TN, USA
Show all (33)

GenMark Diagnostics Financials and Metrics

GenMark Diagnostics Revenue

Embed Graph
View revenue for all periods
GenMark Diagnostics's revenue was reported to be $88.02 m in FY, 2019
USD

Revenue (Q2, 2020)

40.1m

Gross profit (Q2, 2020)

15.9m

Gross profit margin (Q2, 2020), %

39.5%

Net income (Q2, 2020)

(4.7m)

EBIT (Q2, 2020)

(2.7m)

Market capitalization (12-Nov-2020)

975.4m

Closing stock price (12-Nov-2020)

13.6

Cash (30-Sept-2020)

57.8m

EV

1.0b
GenMark Diagnostics's current market capitalization is $975.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019

Revenue

5.0m20.5m27.4m30.6m39.4m49.3m52.5m88.0m

Revenue growth, %

12%29%25%

Cost of goods sold

6.2m11.6m15.9m13.1m15.3m19.7m32.5m59.4m

Gross profit

(1.2m)8.8m11.5m17.5m24.1m29.6m20.0m28.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

901.0k1.3m2.2m3.6m5.3m11.1m5.2m4.6m7.9m6.6m6.3m10.1m7.6m8.5m11.1m12.5m10.8m12.5b12.4m11.6m14.9m15.8m18.4m20.9m38.7m40.1m

Cost of goods sold

1.3m1.8m1.7m2.2m3.0m5.0m3.2m4.1m3.7m3.2m2.7m4.0m3.3m3.4m4.4m4.7m4.4m6.4b7.5m7.4m10.5m10.2m11.8m13.9m22.6m24.2m

Gross profit

(393.0k)(469.0k)472.0k1.4m2.2m6.1m2.0m499.0k4.2m3.4m3.6m6.1m4.4m5.1m6.7m7.8m6.5m6.2b4.9m4.2m4.4m5.6m6.6m7.1m16.2m15.9m

Gross profit Margin, %

(44%)(36%)22%40%42%55%39%11%53%51%57%61%57%60%60%62%60%49%40%36%30%36%36%34%42%40%
show all
Annual
USDY, 2009Y, 2010Y, 2011FY, 2011Y, 2012FY, 2012Y, 2013FY, 2013FY, 2014Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2019

Cash

16.5m51.3m25.3m25.3m51.3m51.3m35.7m35.7m36.9m36.9m35.4m35.4m16.0m26.8m44.4m

Accounts Receivable

1.1m3.2m2.9m4.9m6.8m10.7m16.8m

Prepaid Expenses

322.0k226.0k552.0k575.0k591.0k1.8m1.9m

Inventories

2.2m2.0m2.1m2.1m2.1m2.1m3.1m3.1m3.1m10.9m11.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

43.5m31.0m23.8m64.2m53.4m32.0m18.8m63.3m27.9m26.8m25.7m36.9m32.1m34.2m27.9m29.6m19.3m13.2m88.4m27.2m28.9m25.0m23.7m24.3m26.3m82.4m57.8m

Accounts Receivable

640.0k724.0k1.1m1.3m1.2m4.4m4.4m2.4m2.6m2.1m2.7m4.4m4.3m5.4m5.4m5.1m7.3m7.8m7.1m9.9m6.8m10.4m25.7m17.9m16.2m

Prepaid Expenses

495.0k428.0k135.0k192.0k183.0k382.0k772.0k682.0k627.0k1.1m1.2m770.0k874.0k623.0k1.3m1.2m1.3m2.0m1.9m1.9m2.1m2.1m1.8m1.8m2.8m

Inventories

1.2m2.0m2.1m1.9m2.1m3.2m3.4m2.0m1.8m1.2m1.5m2.1m2.0m2.7m2.4m2.6m4.2m9.0m7.1m7.1m8.8m11.3m9.9m12.6m9.9m14.9m19.6m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019

Net Income

(24.0m)(22.1m)(33.6m)(38.3m)(42.2m)(50.6m)(61.8m)(47.3m)

Depreciation and Amortization

1.3m1.2m2.5m2.7m3.4m3.9m5.3m7.3m

Inventories

(1.7m)(880.0k)(1.3m)(229.0k)(1.3m)(3.4m)(10.5m)(6.5m)

Accounts Payable

378.0k728.0k1.3m85.0k(757.0k)4.1m2.6m1.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(12.2m)(18.5m)(5.6m)(11.2m)(17.4m)(4.2m)(12.2m)(23.0m)(8.8m)(20.0m)(29.7m)(9.9m)(33.4m)(13.0m)(25.9m)(37.9m)(25.4m)(37.1m)(7.0m)

Depreciation and Amortization

622.0k948.0k264.0k576.0k918.0k498.0k1.0m1.9m574.0k1.2m1.9m797.0k2.7m900.0k1.8m2.7m2.5m3.8m3.5m5.3m3.6m5.4m1.8m3.5m5.4m

Inventories

(275.0k)(1.4m)757.0k1.1m(402.0k)(1.5m)(1.8m)(216.0k)169.0k608.0k209.0k(366.0k)(980.0k)501.0k306.0k1.0m(2.6m)(4.8m)(353.0k)(3.8m)(1.4m)(5.5m)920.0k(5.0m)(10.2m)

Accounts Payable

1.4m510.0k(112.0k)369.0k907.0k129.0k(310.0k)570.0k(449.0k)(501.0k)(318.0k)(775.0k)(358.0k)617.0k1.3m916.0k(3.1m)(1.5m)(1.9m)(3.4m)(1.1m)345.0k(1.6m)3.6m7.4m
show all
Show all financial metrics

GenMark Diagnostics Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents Issued

130 120 100

Patents Pending

25 35 30
Show all operating metrics

GenMark Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

GenMark Diagnostics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

GenMark Diagnostics Online and Social Media Presence

GenMark Diagnostics's Trends

Embed Graph

GenMark Diagnostics Company Culture

  • Overall Culture

    C+

    73/100

  • CEO Rating

    F

    53/100

  • Compensation

    C

    67/100

Learn more on Comparably

GenMark Diagnostics News and Updates

November 05, 2020

GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum

CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTec…
October 09, 2020

Thinking about trading options or stock in GenMark Diagnostics, General Electric, Gilead Sciences, American Airlines, or Penn National Gaming?

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNMK, GE, GILD, AAL, and PENN. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
March 02, 2020

GenMark Diagnostics Reports Fourth Quarter and Full Year 2019 Results

CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2019.
April 15, 2019

GenMark Diagnostics Schedules First Quarter 2019 Financial Results Conference Call for April 30, 2019

CARLSBAD, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, April 30, 2019. Management will hold a conference call to review the company's financial performa…
April 15, 2019

GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Gram-Negative Panel

Complete Suite of ePlex Blood Culture Identification Panels Now Available in the U.S. Complete Suite of ePlex Blood Culture Identification Panels Now Available in the U.S.
February 07, 2019

GenMark Diagnostics Schedules Fourth Quarter and Full Year 2018 Financial Results Conference Call for February 21, 2019

CARLSBAD, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Thursday, February 21, 2019. Management will hold a conference call to review the Company's financial perf…
Show more

GenMark Diagnostics Blogs

October 28, 2020

GenMark Diagnostics Reports Third Quarter 2020 Results

GenMark Diagnostics Reports Third Quarter 2020 Results Content Import Wed, 10/28/2020 - 16:08 GenMark Diagnostics Reports Third Quarter 2020 Results October 28, 2020 This release is a backfill from a News Wire Earnings CARLSBAD, Cali…
October 14, 2020

GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020

GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020 Content Import Wed, 10/14/2020 - 17:21 GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020 October 14, 2020 This release is a backfill fr…
October 08, 2020

GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020

Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth CARLSBAD, Calif. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary
September 14, 2020

GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens helps health care professionals prepare for flu season RP2 Panel at a Glance GenMark’s ePlex® Respiratory Pathogen Panel 2 ( RP2 ) has achieved CE mark. RP2 provides results in less than two hours for more than
August 17, 2020

GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test

GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test Content Import Mon, 08/17/2020 - 08:01 GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test August 17, 2020 …
August 04, 2020

GenMark Diagnostics Reports Second Quarter 2020 Results

CARLSBAD, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020 . Second Quarter 2020 Highlights Total revenue of
Show more

 GenMark Diagnostics Frequently Asked Questions

  • When was GenMark Diagnostics founded?

    GenMark Diagnostics was founded in 2010.

  • Who are GenMark Diagnostics key executives?

    GenMark Diagnostics's key executives are Scott Mendel, Michael Gleeson and Johnny Ek.

  • How many employees does GenMark Diagnostics have?

    GenMark Diagnostics has 437 employees.

  • What is GenMark Diagnostics revenue?

    Latest GenMark Diagnostics annual revenue is $88 m.

  • What is GenMark Diagnostics revenue per employee?

    Latest GenMark Diagnostics revenue per employee is $201.4 k.

  • Who are GenMark Diagnostics competitors?

    Competitors of GenMark Diagnostics include Abaxis, In Vitro Technologies and Laborie.

  • Where is GenMark Diagnostics headquarters?

    GenMark Diagnostics headquarters is located at 5964 La Place Ct, Carlsbad.

  • Where are GenMark Diagnostics offices?

    GenMark Diagnostics has offices in Carlsbad, Albany, Atlanta, Birmingham and in 29 other locations.

  • How many offices does GenMark Diagnostics have?

    GenMark Diagnostics has 33 offices.